Elagolix(Abbott) enters Phase III trial for Endometrosis

Abbott (in cooperation with Neurocrine Biosciences) announced the initiation of a pivotal Phase III clinical trial designed to evaluate the safety and efficacy of elagolix, an orally-active non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, in female patients with Endometriosis. The Phase III trial (M12-665) is a 24-week, multinational, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 875 women, age 18 to 49, with moderate-to-severe endometriosis-associated pain. It will be conducted at approximately 160 sites in the United States, Puerto Rico and Canada.